Stay updated with breaking news from Vaccine Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans Findings support further clinical development for prevention and treatment of dengue, which impacts millions
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humansFindings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate changeResearch builds on Johnson & Johnson’s endu...
15.03.2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human ... Seite 1
Halfway through a $475 million Biden administration campaign promoting the new bivalent COVID booster, only about 1 of 9 Americans have chosen to get the jab.
Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will reflect on the past year of the COVID-19 pandemic and discuss their contribution to vaccine development. They will also discuss what is needed to prepare or respond faster to other infectious agents, and how to assess the impact of SARS-CoV-2 variants of concern (VOC) on vaccine/drug efficacy. The webinar will also highlight the difference between a wild-type neutralization assay and a surrogate pseudoparticle neutralizati...